

Area Prescribing Group report

Date: 04 September 2026 **Quorate:** Yes

The items in this report are supported by the area prescribing group (APG) and approval by NHS Cheshire and Merseyside Integrated Care Board (ICB) is detailed below.

All document links provided for any CMAPG recommendations can be found in the [Cheshire and Merseyside formulary](#) which will also be updated to reflect these changes.

The legacy Cheshire formulary, and the legacy Pan Mersey APC website and formulary are now closed. Legacy documents are available by using the search function of the [Cheshire and Merseyside formulary](#).

CMAPG governance documents are hosted on the [Prescribing](#) section of the NHS Cheshire and Merseyside website.

New medicines NICE TAs

Proposal	Notes	Financial implications	Approval
Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis RAG designation: Green APG subgroup: 14 Aug 2026 APG: 04 Sep 2026	Date of NICE TA publication: 09 July 2026 Approval for implementation: 90 days Deadline for implementation: 07 Oct 2026 Green statement in line with NICE TA1175 . Glycopyrronium bromide cream (Axxidrox) is the first licensed product for the topical treatment of	The estimated additional part-year cost of implementing this NICE TA across Cheshire and Merseyside is £6,500 in 2026-27.	MOP: 17 Sept 2026, clinically supported by MOP group. ICB Executive Committee: 01 Oct 2026, approved by ICB Executive Committee.

	severe primary axillary hyperhidrosis in adults. It is recommended as an option where lifestyle advice and topical aluminium-based antiperspirants and oral antimuscarinics have failed to control symptoms, or are contraindicated or not tolerated. A wider review of the formulary section will be undertaken as oral antimuscarinic drugs used for hyperhidrosis are Amber Initiated, and this presents a pathway issue. Unlicensed glycopyrrolate in cetomacrogol cream and glycopyrronium topical solution may no longer have a role in view of the licensed product.		
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes RAG designation: Red APG subgroup: 14 Aug 2026 APG: 04 Sep 2026	Date of NICE TA publication: 09 July 2026 Approval for implementation: 90 days Deadline for implementation: 07 Oct 2026 Red RAG in line with NICE TA1176. Teplizumab is a new, immunomodulatory treatment for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes. It is administered by intravenous infusion once daily for 14 consecutive days.	Costs approved for 6 patients in 2026-27 based on Diabetes Network estimates.	MOP: 17 Sept 2026, clinically supported by MOP group. ICB Executive Committee: 01 Oct 2026, approved by ICB Executive Committee.

	A new pathway is required, including confirmation of stage 2 type 1 diabetes, specialist assessment and follow-up, infusion capacity including weekend delivery, workforce training and clinical governance. Teplizumab should only be used in designated centres. The ICB is working with local clinicians and regional colleagues to develop detailed implementation proposals for designated centres. Completion of a Blueteq form is required.		
--	---	--	--